Plasma fibronectin is a prognostic biomarker of disability in Parkinson’s disease: a prospective, multicenter cohort study
Abstract In a prospective longitudinal study with 218 Parkinson’s disease (PD) patients in the discovery cohort and 84 in the validation cohort, we aimed to identify novel blood biomarkers predicting disability milestones in PD. Through Least Absolute Shrinkage and Selection Operator-Cox (Lasso-Cox)...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | npj Parkinson's Disease |
| Online Access: | https://doi.org/10.1038/s41531-024-00865-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841559818173677568 |
|---|---|
| author | Shuzhen Zhu Hualin Li Zifeng Huang Yiheng Zeng Jianmin Huang Guixia Li Shujuan Yang Hang Zhou Zihan Chang Zhenchao Xie Rongfang Que Xiaobo Wei Minzi Li Yanran Liang Wenbiao Xian Mengyan Li Ying Pan Fanheng Huang Lin Shi Chengwu Yang Chao Deng Lucia Batzu Karolina Poplawska-Domaszewicz Shuhan Chen Ling-Ling Chan K Ray Chaudhuri Eng-King Tan Qing Wang |
| author_facet | Shuzhen Zhu Hualin Li Zifeng Huang Yiheng Zeng Jianmin Huang Guixia Li Shujuan Yang Hang Zhou Zihan Chang Zhenchao Xie Rongfang Que Xiaobo Wei Minzi Li Yanran Liang Wenbiao Xian Mengyan Li Ying Pan Fanheng Huang Lin Shi Chengwu Yang Chao Deng Lucia Batzu Karolina Poplawska-Domaszewicz Shuhan Chen Ling-Ling Chan K Ray Chaudhuri Eng-King Tan Qing Wang |
| author_sort | Shuzhen Zhu |
| collection | DOAJ |
| description | Abstract In a prospective longitudinal study with 218 Parkinson’s disease (PD) patients in the discovery cohort and 84 in the validation cohort, we aimed to identify novel blood biomarkers predicting disability milestones in PD. Through Least Absolute Shrinkage and Selection Operator-Cox (Lasso-Cox) regression, developed nomogram predictive model and Linear mixed-effects models, we identified low level of plasma fibronectin (pFN) as one of the best-performing risk markers in predicting disability milestones. A low level of pFN was associated with a short milestone-free survival period in PD. Longitudinal analysis showed an annual decline in the rate of pFN was significantly associated with the annual elevation rate in the Hoehn-Yahr stage. Moreover, pFN level was negatively correlated with phosphorylated α-synuclein, and a low level of pFN was associated with BBB disruption in the striatum on neuroimaging, providing evidence for pFN’s role in PD progression. We finally identified pFN as a novel blood biomarker that predicted first-milestone disability in PD. |
| format | Article |
| id | doaj-art-74b199cab0574236a1d2996f0df588f2 |
| institution | Kabale University |
| issn | 2373-8057 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Parkinson's Disease |
| spelling | doaj-art-74b199cab0574236a1d2996f0df588f22025-01-05T12:12:05ZengNature Portfolionpj Parkinson's Disease2373-80572025-01-0111111210.1038/s41531-024-00865-1Plasma fibronectin is a prognostic biomarker of disability in Parkinson’s disease: a prospective, multicenter cohort studyShuzhen Zhu0Hualin Li1Zifeng Huang2Yiheng Zeng3Jianmin Huang4Guixia Li5Shujuan Yang6Hang Zhou7Zihan Chang8Zhenchao Xie9Rongfang Que10Xiaobo Wei11Minzi Li12Yanran Liang13Wenbiao Xian14Mengyan Li15Ying Pan16Fanheng Huang17Lin Shi18Chengwu Yang19Chao Deng20Lucia Batzu21Karolina Poplawska-Domaszewicz22Shuhan Chen23Ling-Ling Chan24K Ray Chaudhuri25Eng-King Tan26Qing Wang27Department of Neurology, Zhujiang Hospital of Southern Medical UniversityDepartment of Neurology, Zhujiang Hospital of Southern Medical UniversityDepartment of Neurology, Zhujiang Hospital of Southern Medical UniversityDepartment of Neurology, Zhujiang Hospital of Southern Medical UniversityDepartment of Neurology, Zhujiang Hospital of Southern Medical UniversityDepartment of Neurology, Zhujiang Hospital of Southern Medical UniversityDepartment of Neurology, Zhujiang Hospital of Southern Medical UniversityDepartment of Neurology, Zhujiang Hospital of Southern Medical UniversityDepartment of Neurology, Zhujiang Hospital of Southern Medical UniversityDepartment of Neurology, Zhujiang Hospital of Southern Medical UniversityDepartment of Neurology, Zhujiang Hospital of Southern Medical UniversityDepartment of Neurology, Zhujiang Hospital of Southern Medical UniversityDepartment of Neurology, Zhujiang Hospital of Southern Medical UniversityDepartment of Neurology, Sun Yat-Sen Memorial Hospital of Sun Yat-sen UniversityDepartment of Neurology, The First Affiliated Hospital of Sun Yat-sen UniversityDepartment of Neurology, Guangzhou First People’s Hospital of South China University of TechnologyDepartment of Neurology, The Second Affiliated Hospital of Guangzhou Medical UniversityDepartment of Radiology, Zhujiang Hospital of Southern Medical UniversityDepartment of Imaging and Interventional Radiology, The Chinese University of Hong KongDivision of Biostatistics and Health Services Research, Department of MassachusettPopulation and Quantitative Health Sciences, T.H. Chan School of Medicine, UMass Chan Medical SchoolSchool of Medical, Indigenous and Health Sciences, and Molecular Horizons, University of WollongongParkinson Foundation International Centre of Excellence at King’s College Hospital, and Kings CollegeParkinson Foundation International Centre of Excellence at King’s College Hospital, and Kings CollegeGuangdong Experimental High SchoolDepartment of Neurology, Singapore General HospitalParkinson Foundation International Centre of Excellence at King’s College Hospital, and Kings CollegeDepartment of Neurology, Singapore General HospitalDepartment of Neurology, Zhujiang Hospital of Southern Medical UniversityAbstract In a prospective longitudinal study with 218 Parkinson’s disease (PD) patients in the discovery cohort and 84 in the validation cohort, we aimed to identify novel blood biomarkers predicting disability milestones in PD. Through Least Absolute Shrinkage and Selection Operator-Cox (Lasso-Cox) regression, developed nomogram predictive model and Linear mixed-effects models, we identified low level of plasma fibronectin (pFN) as one of the best-performing risk markers in predicting disability milestones. A low level of pFN was associated with a short milestone-free survival period in PD. Longitudinal analysis showed an annual decline in the rate of pFN was significantly associated with the annual elevation rate in the Hoehn-Yahr stage. Moreover, pFN level was negatively correlated with phosphorylated α-synuclein, and a low level of pFN was associated with BBB disruption in the striatum on neuroimaging, providing evidence for pFN’s role in PD progression. We finally identified pFN as a novel blood biomarker that predicted first-milestone disability in PD.https://doi.org/10.1038/s41531-024-00865-1 |
| spellingShingle | Shuzhen Zhu Hualin Li Zifeng Huang Yiheng Zeng Jianmin Huang Guixia Li Shujuan Yang Hang Zhou Zihan Chang Zhenchao Xie Rongfang Que Xiaobo Wei Minzi Li Yanran Liang Wenbiao Xian Mengyan Li Ying Pan Fanheng Huang Lin Shi Chengwu Yang Chao Deng Lucia Batzu Karolina Poplawska-Domaszewicz Shuhan Chen Ling-Ling Chan K Ray Chaudhuri Eng-King Tan Qing Wang Plasma fibronectin is a prognostic biomarker of disability in Parkinson’s disease: a prospective, multicenter cohort study npj Parkinson's Disease |
| title | Plasma fibronectin is a prognostic biomarker of disability in Parkinson’s disease: a prospective, multicenter cohort study |
| title_full | Plasma fibronectin is a prognostic biomarker of disability in Parkinson’s disease: a prospective, multicenter cohort study |
| title_fullStr | Plasma fibronectin is a prognostic biomarker of disability in Parkinson’s disease: a prospective, multicenter cohort study |
| title_full_unstemmed | Plasma fibronectin is a prognostic biomarker of disability in Parkinson’s disease: a prospective, multicenter cohort study |
| title_short | Plasma fibronectin is a prognostic biomarker of disability in Parkinson’s disease: a prospective, multicenter cohort study |
| title_sort | plasma fibronectin is a prognostic biomarker of disability in parkinson s disease a prospective multicenter cohort study |
| url | https://doi.org/10.1038/s41531-024-00865-1 |
| work_keys_str_mv | AT shuzhenzhu plasmafibronectinisaprognosticbiomarkerofdisabilityinparkinsonsdiseaseaprospectivemulticentercohortstudy AT hualinli plasmafibronectinisaprognosticbiomarkerofdisabilityinparkinsonsdiseaseaprospectivemulticentercohortstudy AT zifenghuang plasmafibronectinisaprognosticbiomarkerofdisabilityinparkinsonsdiseaseaprospectivemulticentercohortstudy AT yihengzeng plasmafibronectinisaprognosticbiomarkerofdisabilityinparkinsonsdiseaseaprospectivemulticentercohortstudy AT jianminhuang plasmafibronectinisaprognosticbiomarkerofdisabilityinparkinsonsdiseaseaprospectivemulticentercohortstudy AT guixiali plasmafibronectinisaprognosticbiomarkerofdisabilityinparkinsonsdiseaseaprospectivemulticentercohortstudy AT shujuanyang plasmafibronectinisaprognosticbiomarkerofdisabilityinparkinsonsdiseaseaprospectivemulticentercohortstudy AT hangzhou plasmafibronectinisaprognosticbiomarkerofdisabilityinparkinsonsdiseaseaprospectivemulticentercohortstudy AT zihanchang plasmafibronectinisaprognosticbiomarkerofdisabilityinparkinsonsdiseaseaprospectivemulticentercohortstudy AT zhenchaoxie plasmafibronectinisaprognosticbiomarkerofdisabilityinparkinsonsdiseaseaprospectivemulticentercohortstudy AT rongfangque plasmafibronectinisaprognosticbiomarkerofdisabilityinparkinsonsdiseaseaprospectivemulticentercohortstudy AT xiaobowei plasmafibronectinisaprognosticbiomarkerofdisabilityinparkinsonsdiseaseaprospectivemulticentercohortstudy AT minzili plasmafibronectinisaprognosticbiomarkerofdisabilityinparkinsonsdiseaseaprospectivemulticentercohortstudy AT yanranliang plasmafibronectinisaprognosticbiomarkerofdisabilityinparkinsonsdiseaseaprospectivemulticentercohortstudy AT wenbiaoxian plasmafibronectinisaprognosticbiomarkerofdisabilityinparkinsonsdiseaseaprospectivemulticentercohortstudy AT mengyanli plasmafibronectinisaprognosticbiomarkerofdisabilityinparkinsonsdiseaseaprospectivemulticentercohortstudy AT yingpan plasmafibronectinisaprognosticbiomarkerofdisabilityinparkinsonsdiseaseaprospectivemulticentercohortstudy AT fanhenghuang plasmafibronectinisaprognosticbiomarkerofdisabilityinparkinsonsdiseaseaprospectivemulticentercohortstudy AT linshi plasmafibronectinisaprognosticbiomarkerofdisabilityinparkinsonsdiseaseaprospectivemulticentercohortstudy AT chengwuyang plasmafibronectinisaprognosticbiomarkerofdisabilityinparkinsonsdiseaseaprospectivemulticentercohortstudy AT chaodeng plasmafibronectinisaprognosticbiomarkerofdisabilityinparkinsonsdiseaseaprospectivemulticentercohortstudy AT luciabatzu plasmafibronectinisaprognosticbiomarkerofdisabilityinparkinsonsdiseaseaprospectivemulticentercohortstudy AT karolinapoplawskadomaszewicz plasmafibronectinisaprognosticbiomarkerofdisabilityinparkinsonsdiseaseaprospectivemulticentercohortstudy AT shuhanchen plasmafibronectinisaprognosticbiomarkerofdisabilityinparkinsonsdiseaseaprospectivemulticentercohortstudy AT linglingchan plasmafibronectinisaprognosticbiomarkerofdisabilityinparkinsonsdiseaseaprospectivemulticentercohortstudy AT kraychaudhuri plasmafibronectinisaprognosticbiomarkerofdisabilityinparkinsonsdiseaseaprospectivemulticentercohortstudy AT engkingtan plasmafibronectinisaprognosticbiomarkerofdisabilityinparkinsonsdiseaseaprospectivemulticentercohortstudy AT qingwang plasmafibronectinisaprognosticbiomarkerofdisabilityinparkinsonsdiseaseaprospectivemulticentercohortstudy |